Rare Disease Report

Myeloproliferative Neoplasms

UT Health Cancer Center Director Ruben Mesa, MD, explains the anemia that can sometimes come with MPN-associated myelofibrosis, and the pertinent data presented at ASH 2017.
Data presented at the 59th Annual American Society of Hematology Meeting and Exposition concludes that Sotatercept is effective in patients with MPN-associated myelofibrosis and anemia.
The first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of myelofibrosis (MF), according to Imago BioSciences.
A Phase 1 clinical study testing CAR T-cell therapy, UCART123,to treat blastic plasmacytoid dendritic cell neoplasm at the MD Anderson Cancer Center has begun.
In this video clip, Srdan Verstovsek, MD PhD; and Jamile M. Shammo, MD discuss the presentation of polycythemia vera and NCCN Guidelines for myeloproliferative neoplasms
The FDA has approved Beckman Coulter's ClearLLab Reagents to help diagnose numerous rare blood cancers, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Two studies observed that aerobic activity, massage, yoga, and strength training significantly reduced disease burden using the MPN-SAF TSS scale.
Patients with uncontrolled PV have an increased risk of cardiovascular complications such as stroke, pulmonary embolism, deep vein thrombosis and heart attack.
Ruben Mesa, MD of the Mayo Clinic in Scottsdale Arizona talks about two approaches to treating polycythemia vera, and essential thrombocythemia that use interferons.
Ruben Mesa, MD of the Mayo Clinic in Scottsdale Arizona talks about two approaches to treating polycythemia vera, and essential thrombocythemia that use interferons.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.